A Promising Preliminary Study of Aripiprazole for Treatment-Resistant Childhood Obsessive-Compulsive Disorder

Basit Öğe Kaydı
dc.contributor.authorErcan E.S.
dc.contributor.authorArdic U.A.
dc.contributor.authorErcan E.
dc.contributor.authorYuce D.
dc.contributor.authorDurak S.
dc.date.accessioned2019-10-26T21:22:59Z
dc.date.available2019-10-26T21:22:59Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Obsessive-compulsive disorder (OCD) is a relatively frequent disease in childhood, which is generally treated with selective serotonin reuptake inhibitors (SSRIs) and/or clomipramine and cognitive behavioral therapy (CBT). However, nearly half of the cases are treatment resistant. Aripiprazole was shown to be beneficial in augmentation therapy in treatment-refractory OCD. This study evaluated its effectiveness as a single agent in these cases. Methods: Sixteen children (nine girls, seven boys), who were nonresponders to treatment with at least two types of SSRIs and CBT, were administered 12 weeks of aripiprazole treatment with a mean dose of 4.75 mg/day (range: 2-7.5 mg/day). Treatment outcomes were evaluated by the Childhood Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and the Clinical Global Impressions-Severity and Improvement (CGI-S and CGI-I) scales. Results: Children with a mean age of 10.9±2.9 years had severe obsessive compulsive symptoms at baseline, and >80% of them had another comorbid psychiatric disease. Significant improvements in symptoms were achieved after 12 weeks of aripiprazole treatment, which were evaluated by significant decreases in symptom scores in the CY-BOCS, and improvements in CGI-I scores. Conclusions: This very small study of aripiprazole, given to children with OCD resistant to at least 12 weeks treatment with at least two SSRIs and CBT, demonstrated striking improvement in CGI scores (all subsets, p?0.002) for 13 of 16 children, and halved all CY-BOCS subscores after ~12 weeks of treatment. © 2015, Mary Ann Liebert, Inc.en_US
dc.identifier.doi10.1089/cap.2014.0128en_US
dc.identifier.endpage584en_US
dc.identifier.issn1044-5463
dc.identifier.issue7en_US
dc.identifier.pmid26375768en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage580en_US
dc.identifier.urihttps://doi.org/10.1089/cap.2014.0128
dc.identifier.urihttps://hdl.handle.net/11454/17021
dc.identifier.volume25en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.ispartofJournal of Child and Adolescent Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA Promising Preliminary Study of Aripiprazole for Treatment-Resistant Childhood Obsessive-Compulsive Disorderen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu